The prevalence of pediatric asthma, mental health conditions, and other chronic conditions has increased since 2000.

The prevalence of internalizing behaviors increased among adolescents, while other mental and behavioral health risks decreased.

Significantly more adolescent patients receiving baricitinib had hair regrowth compared with patients receiving placebo.

There are significant health disparities between sexual and gender minority populations and their cisgender heterosexual counterparts.

Compared to the general population, individuals with incident hospital-based cannabis use disorder care have an increased risk of death.

Topline data were announced from pivotal phase 3 studies evaluating povorcitinib in adults with moderate to severe hidradenitis suppurativa.

Patients undergoing BRAF/MEK inhibitor therapy for melanoma more commonly experience VKH-like uveitis compared with other malignancy types.

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

The risk for moderate to severe infection in later childhood was associated with overall infection burden in early life.

Botulinum toxin type A was seen to be safe and effective for treating facial paralysis following surgery, improving facial symmetry.

The change limits treatment options for veterans with gender dysphoria, who are up to 20 times more likely to experience suicidal thoughts.

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.